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Abstract
Aim—The aim of this study was to determine the population pharmacokinetics of darbepoetin alfa 
in hypothermic neonates with hypoxic-ischemic encephalopathy treated with hypothermia.
Methods—Neonates ≥36 weeks gestation and <12 h postpartum with moderate to severe 
hypoxic-ischemic encephalopathy who were undergoing hypothermia treatment were recruited in 
this randomized, multicenter, investigational, new drug pharmacokinetic study. Two intravenous 
darbepoetin alfa treatment groups were evaluated: 2 and 10 μg/kg. Serum erythropoietin 
concentrations were measured using an enzyme-linked immunosorbent assay. Monolix 4.3.1 was 
used to estimate darbepoetin alfa clearance and volume of distribution. Covariates tested included: 
birthweight, gestational age, postnatal age, postmenstrual age, sex, Sarnat score, and study site.
Results—Darbepoetin alfa pharmacokinetics were well described by a one-compartment model 
with exponential error. Clearance and the volume of distribution were scaled by birthweight 
(centered on the mean) a priori. Additionally, gestational age (also centered on the mean) 
significantly affected darbepoetin alfa clearance. Clearance and volume of distribution were 
estimated as 0.0465 L/h (95 % confidence interval 0.0392–0.0537) and 1.58 L (95 % confidence 
interval 1.29–1.87), respectively.
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Conclusions—A one-compartment model successfully described the pharmacokinetics of 
darbepoetin alfa among hypothermic neonates treated for hypoxic-ischemic encephalopathy. 
Clearance decreased with increasing gestational age.
1 Introduction
Hypoxic-ischemic encephalopathy (HIE) affects 1.5 infants per 1000 live births in developed 
countries [1]. Moderate to severe HIE is associated with severe disabilities in one in four 
survivors and a mortality of 15–25 % [2, 3]. Common disabilities include significant motor 
deficits, cerebral palsy, and persistent developmental delays [2, 3]. The standard of care for 
HIE is moderate hypothermia, in which the neonate is cooled to 33.5°C within 6 h of birth 
and hypothermia is maintained for 72 h [4–6]. A meta-analysis published by Edwards et al. 
[3] evaluated the neurologic outcomes of infants who were randomized to receive moderate 
hypothermia or normothermia and compared their clinical outcomes after a minimum of 18 
months of follow-up. The authors found that the case fatality rate decreased from 33 to 26 % 
and abnormal neurologic outcomes at 18–22 months decreased from 40 to 28 % comparing 
normothermia with moderate hypothermia, respectively. A similar analysis by Tagin et al. 
[7] with 1214 newborns found that with hypothermia treatment, the risk ratio of death or 
major neurodevelopmental disability was 0.76 (95 % confidence interval 0.69–0.84) and the 
rate of survival with normal neurologic function at 18 months of age was improved (1.64; 
1.36–1.95). While these results are encouraging, moderate to severe HIE despite 
hypothermia treatment still causes substantial mortality and morbidity, which supports the 
need for adjunctive therapies to improve outcomes.
Erythropoietin-stimulating agents have been shown to mediate adaptive tissue responses 
following stressful insults and may be neuroprotective [8, 9]. This is consistent with studies 
that have shown that the erythropoietin receptor is expressed throughout the human brain 
[10–12]. Preclinical studies using mice demonstrated that erythropoietin efficiently crosses 
the blood-brain barrier [13]. Daily administration of erythropoietin to animals has conferred 
histologic and behavioral neuroprotection after experimental intracerebral hemorrhage [14]. 
In two clinical trials, erythropoietin was found to exert neuroprotective effects among 
neonates who did not undergo hypothermia treatment [15, 16]. More recently, the Neonatal 
Erythropoietin in Asphyxiated Term Neonates trial showed that erythropoietin could be 
administered safely to neonates undergoing therapeutic hypothermia [17].
Darbepoetin alfa is a synthetic molecule designed to mimic the effects of erythropoietin [18–
20]. Site-directed mutagenesis at five amino acid locations (Ala30Asn, His32Thr, Pro87Val, 
Trp88Asn, and Pro90Thr) added two additional N-linked carbohydrate chains, which extend 
the half-life [18–20]. Preclinical studies with darbepoetin alfa have shown that it crosses the 
blood-brain barrier and displays comparable neuroprotective activity when compared with 
erythropoietin [13, 21]. In animal models, weekly administration of darbepoetin alfa 
conferred histologic and behavioral neuroprotection after experimental intracerebral 
hemorrhage [14]. Early clinical studies have demonstrated the safety of darbepoetin alfa 
among preterm and term neonates [22, 23]. The aim of this study was to determine the 
population pharmacokinetics of darbepoetin alfa among neonates undergoing therapeutic 
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hypothermia for the treatment of HIE in support of larger studies to evaluate its efficacy for 
neuroprotection.
2 Methods
2.1 Subjects and Study Design
This was a multicenter, placebo-controlled, randomized, double-blind, pharmacokinetic and 
safety trial that was approved by each site’s institutional review board (NCT01471015). The 
population pharmacokinetic analysis of this trial is described herein. Centers included the 
Seattle Children’s Hospital, Primary Children’s Hospital, University of Utah Hospital, 
Intermountain Medical Center, McKay-Dee Hospital, Vanderbilt Children’s Hospital, and 
the University of New Mexico Children’s Hospital. Parental permission was obtained before 
conducting any study procedures. Inclusion criteria included: gestational age ≥36 weeks, 
<12 h of age; evidence of moderate to severe hypothermia based on a modified Sarnat score 
of 2–3 [4]; and severe fetal or early (< 1 h of age) neonatal acidosis. Additional criteria 
included evidence of an acute intrauterine event, and either a 10-min Apgar score of ≤5 or 
assisted ventilation initiated at birth that continued for ≥10 min was required if a blood gas 
was not available or a blood gas at <1 h of age had a pH between 7.01 and 7.15, or a base 
deficit between 10 and 15.9 mEg/L. Neonates were excluded from the trial if they had a 
major congenital and/or chromosomal abnormality, severe growth restriction (≤1800 g at 
birth), a prenatal diagnosis of brain abnormality or hydrocephalus, a hematocrit >65 %, a 
platelet count >600,000/dL, neutropenia (absolute neutrophil count <500 μL), were 
receiving extracorporeal membrane oxygenation, or had a maternal history of major vascular 
thrombosis or multiple fetal losses (three or more spontaneous abortions).
Following informed consent, patients were randomized to one of three study arms: placebo 
(saline), 2 μg/kg, or 10 μg/kg darbepoetin alfa (Aranesp®, Amgen, Thousand Oaks, CA, 
USA). All three groups received therapeutic hypothermia according to the standard of care 
within 6 h of birth, which was maintained for 72 h. Neonates received the darbepoetin alfa 
or placebo dose intravenously over 5 min within 12 h of life, followed by a 2-mL saline 
flush over 5 min.
2.2 Sample Collection
Plasma samples were collected according to a population design, in which patients were 
randomized to one of two sampling schedules in a 1:1 ratio. One group had samples 
collected before treatment and at 4, 12, 24, and 60 h post-dose. The second group had 
samples collected before treatment and at 4, 18, 36, and 72 h post-dose. All blood samples 
were collected by a heel stick or from an arterial or central venous catheter.
2.3 Analytical Assay
Plasma samples were analyzed using a Quantikine IVD™ human erythropoietin ELISA 
(R&D Systems, Minneapolis, MN, USA) according to the manufacturer’s protocol. This 
ELISA cross-reacts with endogenous erythropoietin, which makes it impossible to 
distinguish darbepoetin alfa from endogenous erythropoietin. Standard curves included 2.5 
[lower limit of quantification (LLOQ)], 5.0, 20, 50, 100, and 200 mU/mL of erythropoietin. 
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A weighted (1/x2) quadratic regression model was fitted to each standard curve. Each 
individual sample well was quantified by interpolation, after which, duplicates were 
averaged. Samples that were below the LLOQ were excluded from the analysis (eight 
concentrations, 14 %). If samples were evaluated on more than 1 day, all wells were 
averaged for the final sample quantitation. Duplicates in the standard curve that had an 
intraday coefficient of variation >10 % or samples that had intra- or inter-day coefficients of 
variation >10 % were excluded from the analysis. In addition, standards that did not meet 
the United States Food and Drug Administration guidelines (±20 % for LLOQ, ±15 % for all 
others) were not included in the construction of the standard curve.
2.4 Pharmacokinetic Analysis
All darbepoetin alfa-treated concentrations were normalized to the median placebo 
concentration at the corresponding sampling time to account for the effect of endogenous 
erythropoietin contributions. Darbepoetin alfa pharmacokinetic parameters were estimated 
using a nonlinear mixed-effects model that was implemented in Monolix 4.3.1 (Lixoft, 
Orasy, France) using the stochastic approximation expectation maximization algorithm [24] 
combined with a Markov Chain Monte Carlo procedure. The number of Markov Chain 
Monte Carlo chains was fixed to four. One- and two-compartment structural models were 
evaluated and selected based on their goodness of fit. Model stability was assessed by 
altering the initial estimates for darbepoetin alfa clearance and volume of distribution. 
Unstable models and those that produced erroneous results (e.g., negative parameter 
estimates) were disregarded. Diagnostic plots were used to assess the model’s fit. Individual 
weighted residuals were plotted vs. time and individual predictions. Models were compared 
by assessing the biological plausibility of the parameter estimates, the variability of the 
parameter estimates, and the −2 × log likelihood or the objective function value (OFV).
Model variability and random effects were classified as one of two types of error: between-
subject variability (BSV) and residual unexplained variability (RUV). BSV was assumed to 
be log-normally distributed according to an exponential equation:
(1)
where Pi, is the pharmacokinetic parameter of the ith individual, θpop is the population mean 
for P, and η represents the normally distributed between-subject random effect with a mean 
of zero and a variance of ω2. Additive, proportional, combined additive and proportional, 
and exponential RUV error models were evaluated. The final model used an exponential 
model of the form:
(2)
where Yij is the observed concentration for the ith individual at time j, Ŷij is the individual 
predicted concentration, and ε represents the normally distributed error term with a mean of 
zero and variance of σ2 .
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2.5 Covariate Analysis
Several patient characteristics were tested for their influence on darbepoetin alfa 
pharmacokinetic parameters. The covariates that were tested included birthweight, 
gestational age, postnatal age, postmenstrual age, sex, Sarnat score, and study site. 
Birthweight centered on the mean was included a priori in the model for both clearance and 
the volume of distribution on the basis of its biological plausibility [25]. In addition, 
exponents were fixed at 1 based on model estimates of 1.2 and 0.992. Power, exponential, 
and linear models were evaluated for the remaining covariates. In addition, each covariate 
was also evaluated after it was centered on the population mean. Forward addition was used 
to determine significant covariates. A decrease in the OFV ≥3.84 was considered significant 
for 1 df at p = 0.05 based on the χ2 distribution. Backward elimination was used to remove 
covariates from the model with an increase in the OFV ≥6.63 corresponding to 1 df at p = 
0.01.
2.6 Model Evaluation
Base and final models were evaluated using goodness-of-fit plots. Observed drug 
concentrations were inspected for their correlation with predicted concentrations. The −2 
and +2 region criterion was used to assess the individual weighted residual plots that were 
constructed. Uncertainty in pharmacokinetic parameter estimates was quantitatively assessed 
by calculating standard errors and 95 % confidence intervals for all pharmacokinetic 
parameter estimates. Additionally, normalized prediction distribution errors were plotted 
against time and population-predicted darbepoetin alfa concentrations to assess for model 
misspecification. A prediction-corrected visual predictive check was also performed by 
simulating 1000 darbepoetin alfa concentrations at each time point [26].
3 Results
There were 10 patients with 32 concentration measurements who were randomized to the 
placebo group. In addition, there were 16 patients with 63 concentration measurements who 
received darbepoetin alfa. Supplemental Fig. 1 depicts the time-concentration curve of all 
patients. The demographics for the study subjects at the time of the dose are included in 
Table 1. The data were well described by a one-compartment model with zero-order input 
and first-order elimination as assessed by visual inspection of the diagnostic plots and the 
significant reduction of the OFV. After a priori inclusion of birthweight on clearance and the 
volume of distribution, additional covariate analyses indicated that gestational age centered 
on the mean exerted a significant influence on darbepoetin alfa clearance (decreasing BSV 
from 0.328 to 0.205, Supplemental Fig. 2). After including these covariates, no other 
covariates were found to significantly affect darbepoetin alfa pharmacokinetics. The final 
model estimates are presented in Table 2 and were derived from the following final model:
(3)
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(4)
where CLi is the individual clearance, CLpop is the estimated population clearance, BWTi is 
the individual birth-weight, BWTpop is the mean population birthweight, GAi is the 
individual gestational age, GApop is the mean population gestational age, and θ is the 
estimated exponent for the effect of gestational age on darbepoetin alfa clearance. Similarly, 
Vi is the individual volume of distribution, Vpop is the population estimate, BWTi is the 
individual weight, and BWTpop is the mean population birthweight. Diagnostic plots were 
visually inspected to confirm the selection of the final model (Fig. 1a, b). To further evaluate 
the model, individual weighted residual and normalized prediction distribution error plots 
were examined (Fig. 2a–d). The data were equally distributed around zero and were in the 
−2to +2 range. Additionally, data were simulated to produce a visual predictive check 
comparing the 10th, 50th, and 90th percentiles (Fig. 3). The majority of the simulations were 
within these ranges, demonstrating acceptable agreement between observed concentrations 
and simulated darbepoetin alfa concentrations.
4 Discussion
This is the first study to evaluate the pharmacokinetics of darbepoetin alfa among neonates 
with HIE undergoing therapeutic hypothermia. This study also featured a placebo arm, such 
that endogenous erythropoietin concentrations could be used to normalize erythropoietin 
concentrations for the darbepoetin alfa-treated patients. This study demonstrated that 
darbepoetin alfa pharmacokinetics in neonates with HIE was well described by a one-
compartment model, with a population clearance equal to 0.0465 L/h (0.015 L/h/kg) and 
volume of distribution equal to 1.58 L (0.511 L/kg). Covariate analyses indicated that after 
the inclusion of birthweight on volume of distribution and clearance, gestational age also 
significantly affected clearance, with increasing gestational age associated with decreased 
darbepoetin alfa clearance. Darbepoetin alfa is a synthetic derivative of erythropoietin and is 
primarily cleared by binding to erythropoietin receptors on progenitor cells [27–32]. It has 
been demonstrated in lambs that the clearance of erythropoietin occurs most rapidly in 
fetuses and gets progressively lower as sheep mature to adulthood [33], supporting the 
findings of this study.
A majority of the adult pharmacokinetic studies pooled data from patients who received 
darbepoetin alfa intravenously and via subcutaneous injection [34–36]. These studies used a 
two-compartment model to describe darbepoetin alfa pharmacokinetics [34–36]. It is unclear 
whether the one-compartment model used in the current study performed better than the 
two-compartment model because of sparse sampling in this vulnerable neonatal population 
or whether the pharmacokinetics of darbepoetin alfa are better represented by a one-
compartment model in neonates rather than the two-compartment model seen in adults. The 
only other study to evaluate intravenous darbepoetin alfa pharmacokinetics in neonates was 
conducted in 10 anemic patients with a mean gestational age of 31.1 weeks at birth who did 
not have HIE [22]. The authors found that darbepoetin alfa pharmacokinetics were best 
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described using a mono-exponential model; however, two patients were better fit with a 
dual-exponential pharmacokinetic model. The mean volume of distribution and clearance 
were 1.29 L and 0.0882 L/h, respectively, resulting in a half-life of about 10.1 h. The 
population estimates reported herein resulted in a half-life of 23.6 h. Patients in this 
population analysis were on average 7 weeks older at birth than those in the study conducted 
by Warwood et al. [22]. Unlike prior studies, the current analysis adopted a population 
pharmacokinetic approach, which allowed for the identification of influential covariates that 
were used to reduce the proportion of unexplained variability in darbepoetin alfa 
pharmacokinetic parameters. The population pharmacokinetic model revealed that after 
accounting for the influence of birthweight, darbepoetin alfa clearance was inversely 
correlated with gestational age. This finding suggests that the difference in the mean 
gestational age of the cohort studied by Warwood et al. and that of the cohort included in 
this analysis may explain, at least in part, the difference in darbepoetin alfa half-lives 
reported previously and those observed in this study. Additionally, patients in our study were 
also treated with hypothermia. It is therefore unclear whether the differences in half-lives 
between these studies can be attributed to differences in gestational age, the use of 
therapeutic hypothermia, other unmeasured factors, or a combination of the above.
Some limitations should be considered when interpreting this study’s findings. First, patients 
had differing lengths of hypoxic episodes, which were not quantifiable. Hypoxic episodes 
increase erythropoietin production and it is believed that longer hypoxic episodes result in 
more erythropoietin production [37]. Even with a representative placebo group, it is possible 
that early darbepoetin alfa concentrations may have been overestimated because of higher 
endogenous erythropoietin concentrations at birth among darbepoetin alfa-treated patients. 
Second, the assay used quantifies both darbepoetin alfa and erythropoietin, and as such, 
median concentrations from placebo patients had to be used as a baseline for the treated 
patients. Furthermore, a specific validation for this assay has not been completed in 
neonates, though this assay has been used previously for darbepoetin alfa quantification 
[38]. Additionally, the confidence interval for the BSV for the volume of distribution 
includes zero, which could be attributed to the sparse sampling that was needed to ethically 
and practically conduct this neonatal pharmacokinetic trial. With a larger number of subjects 
and/or additional concentration measurements, it may be possible to improve the precision 
of the BSV estimate for the volume of distribution. Furthermore, the relatively large RUV 
observed in this study (42 %) is in agreement with previous neonatal drug studies and 
emphasizes the difficulty in determining precise pharmacokinetic parameter estimates in this 
highly variable patient population, which undergoes profound developmental changes over 
the first few weeks of life [39]. Last, choosing to include birthweight a priori in the model 
could decrease the predictive performance of the model with the addition of other covariates. 
However, because of biological plausibility, we deemed it important to include birthweight 
in the model as a covariate before testing other covariates.
5 Conclusions
This study presents the first population pharmacokinetic analysis of darbepoetin alfa in 
hypothermic neonates with HIE. This study demonstrated that after accounting for the effect 
of birthweight on clearance and the volume of distribution, gestational age also significantly 
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affected darbepoetin alfa clearance. Gestational age was inversely correlated with clearance, 
confirming results obtained in earlier studies involving fetal, neonatal, and adult sheep. 
Future analyses with larger numbers of subjects and long-term follow-up are warranted to 
further characterize the pharmacokinetics of darbepoetin alfa and their influence on clinical 
outcomes, including death and severe disability.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
Acknowledgments
JKR was supported by the Pharmacotherapy Subspecialty Award from the Primary Children’s Hospital Foundation; 
CS was supported by the American Foundation for Pharmaceutical Education’s Clinical Pharmaceutical Sciences 
Fellowship; MCB and this clinical study were supported by the Thrasher Foundation (10026771-F1); the REDCap 
database used to house the clinical data from the trial was supported by the Center for Clinical and Translational 
Sciences grant (8UL1TR000105 NCATS/NIH).
References
1. Kurinczuk JJ, White-Koning M, Badawi N. Epidemiology of neonatal encephalopathy and hypoxic-
ischaemic encephalopathy. Early Hum Dev. 2010; 86(6):329–38. [PubMed: 20554402] 
2. Shankaran S. Hypoxic-ischemic encephalopathy and novel strategies for neuroprotection. Clin 
Perinatol. 2012; 39(4):919–29. [PubMed: 23164187] 
3. Edwards AD, Brocklehurst P, Gunn AJ, Halliday H, Juszczak E, Levene M, et al. Neurological 
outcomes at 18 months of age after moderate hypothermia for perinatal hypoxic ischaemic 
encephalopathy: synthesis and meta-analysis of trial data. BMJ. 2010; 340:c363. [PubMed: 
20144981] 
4. Shankaran S, Laptook AR, Ehrenkranz RA, Tyson JE, McDonald SA, Donovan EF, et al. Whole-
body hypothermia for neonates with hypoxic-ischemic encephalopathy. N Engl J Med. 2005; 
353(15):1574–84. [PubMed: 16221780] 
5. Gluckman PD, Wyatt JS, Azzopardi D, Ballard R, Edwards AD, Ferriero DM, et al. Selective head 
cooling with mild systemic hypothermia after neonatal encephalopathy: multicentre randomised 
trial. Lancet. 2005; 365(9460):663–670. [PubMed: 15721471] 
6. Azzopardi DV, Strohm B, Edwards AD, Dyet L, Halliday HL, Juszczak E, et al. Moderate 
hypothermia to treat perinatal asphyxial encephalopathy. N Engl J Med. 2009; 361(14):1349–58. 
[PubMed: 19797281] 
7. Tagin MA, Woolcott CG, Vincer MJ, Whyte RK, Stinson DA. Hypothermia for neonatal hypoxic 
ischemic encephalopathy: an updated systematic review and meta-analysis. Arch Pediatr Adolesc 
Med. 2012; 166(6):558–66. [PubMed: 22312166] 
8. Brines ML, Ghezzi P, Keenan S, Agnello D, de Lanerolle NC, Cerami C, et al. Erythropoietin 
crosses the blood-brain barrier to protect against experimental brain injury. Proc Natl Acad Sci 
USA. 2000; 97(19):10526–31. [PubMed: 10984541] 
9. Casals-Pascual C, Idro R, Gicheru N, Gwer S, Kitsao B, Gitau E, et al. High levels of erythropoietin 
are associated with protection against neurological sequelae in African children with cerebral 
malaria. Proc Natl Acad Sci USA. 2008; 105(7):2634–9. [PubMed: 18263734] 
10. Hasselblatt M, Ehrenreich H, Siren AL. The brain erythropoietin system and its potential for 
therapeutic exploitation in brain disease. J Neurosurg Anesthesiol. 2006; 18(2):132–8. [PubMed: 
16628067] 
11. Dame C, Bartmann P, Wolber E, Fahnenstich H, Hofmann D, Fandrey J. Erythropoietin gene 
expression in different areas of the developing human central nervous system. Brain Res Dev 
Brain Res. 2000; 125(1–2):69–74. [PubMed: 11154762] 
Roberts et al. Page 8
Clin Pharmacokinet. Author manuscript; available in PMC 2017 August 26.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
12. Juul SE, Anderson DK, Li Y, Christensen RD. Erythropoietin and erythropoietin receptor in the 
developing human central nervous system. Pediatr Res. 1998; 43(1):40–9. [PubMed: 9432111] 
13. Banks WA, Jumbe NL, Farrell CL, Niehoff ML, Heatherington AC. Passage of erythropoietic 
agents across the blood-brain barrier: a comparison of human and murine erythropoietin and the 
analog darbepoetin alfa. Eur J Pharmacol. 2004; 505(1–3):93–101. [PubMed: 15556141] 
14. Grasso G, Graziano F, Sfacteria A, Carletti F, Meli F, Maugeri R, et al. Neuroprotective effect of 
erythropoietin and darbepoetin alfa after experimental intracerebral hemorrhage. Neurosurgery. 
2009; 65(4):763–769. (discussion 769–70). [PubMed: 19834382] 
15. Zhu C, Kang W, Xu F, Cheng X, Zhang Z, Jia L, et al. Erythropoietin improved neurologic 
outcomes in newborns with hypoxic-ischemic encephalopathy. Pediatrics. 2009; 124(2):e218–26. 
[PubMed: 19651565] 
16. Elmahdy H, El-Mashad AR, El-Bahrawy H, El-Gohary T, El-Barbary A, Aly H. Human 
recombinant erythropoietin in asphyxia neonatorum: pilot trial. Pediatrics. 2010; 125(5):e1135–42. 
[PubMed: 20385632] 
17. Wu YW, Bauer LA, Ballard RA, Ferriero DM, Glidden DV, Mayock DE, et al. Erythropoietin for 
neuroprotection in neonatal encephalopathy: safety and pharmacokinetics. Pediatrics. 2012; 
130(4):683–91. [PubMed: 23008465] 
18. Macdougall IC. Novel erythropoiesis stimulating protein. Semin Nephrol. 2000; 20(4):375–81. 
[PubMed: 10928340] 
19. Ibbotson T, Goa KL. Darbepoetin alfa. Drugs. 2001; 61(14):2097–2104. (discussion 105–106). 
[PubMed: 11735636] 
20. Egrie JC, Browne JK. Development and characterization of novel erythropoiesis stimulating 
protein (NESP). Br J Cancer. 2001; 84(Suppl 1):3–10. [PubMed: 11308268] 
21. Cherian L, Goodman JC, Robertson C. Improved cerebrovascular function and reduced histological 
damage with darbepoietin alfa administration after cortical impact injury in rats. J Pharmacol Exp 
Ther. 2011; 337(2):451–6. [PubMed: 21270134] 
22. Warwood TL, Ohls RK, Lambert DK, Jones C, Scoffield SH, Gupta N, et al. Intravenous 
administration of darbepoetin to NICU patients. J Perinatol. 2006; 26(5):296–300. [PubMed: 
16554846] 
23. Warwood TL, Ohls RK, Wiedmeier SE, Lambert DK, Jones C, Scoffield SH, et al. Single-dose 
darbepoetin administration to anemic preterm neonates. J Perinatol. 2005; 25(11):725–30. 
[PubMed: 16151471] 
24. Kuhn E, Lavielle M. Maximum likelihood estimation in nonlinear mixed effects models. Comput 
Stat Data Anal. 2005; 49:1020–38.
25. Anderson BJ, Allegaert K, Holford NH. Population clinical pharmacology of children: modelling 
covariate effects. Eur J Pediatr. 2006; 165(12):819–29. [PubMed: 16807729] 
26. Bergstrand M, Hooker AC, Wallin JE, Karlsson MO. Prediction-corrected visual predictive checks 
for diagnosing nonlinear mixed-effects models. Aaps J. 2011; 13(2):143–51. [PubMed: 21302010] 
27. Chapel S, Veng-Pedersen P, Hohl RJ, Schmidt RL, McGuire EM, Widness JA. Changes in 
erythropoietin pharmacokinetics following busulfan-induced bone marrow ablation in sheep: 
evidence for bone marrow as a major erythropoietin elimination pathway. J Pharmacol Exp Ther. 
2001; 298(2):820–4. [PubMed: 11454947] 
28. Chapel SH, Veng-Pedersen P, Schmidt RL, Widness JA. Receptor-based model accounts for 
phlebotomy-induced changes in erythropoietin pharmacokinetics. Exp Hematol. 2001; 29(4):425–
31. [PubMed: 11301182] 
29. Freise KJ, Widness JA, Segar JL, Schmidt RL, Veng-Pedersen P. Increased erythropoietin 
elimination in fetal sheep following chronic phlebotomy. Pharm Res. 2007; 24(9):1653–9. 
[PubMed: 17457660] 
30. Jelkmann W. The enigma of the metabolic fate of circulating erythropoietin (Epo) in view of the 
pharmacokinetics of the recombinant drugs rhEpo and NESP. Eur J Haematol. 2002; 69(5–6):265–
74. [PubMed: 12460230] 
31. Stohlman F Jr, Brecher G. Humoral regulation of erythropoiesis: V. Relationship of plasma 
erythropoietine level to bone marrow activity. Proc Soc Exp Biol Med. 1959; 100(1):40–3. 
[PubMed: 13634028] 
Roberts et al. Page 9
Clin Pharmacokinet. Author manuscript; available in PMC 2017 August 26.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
32. Widness JA, Schmidt RL, Hohl RJ, Goldman FD, Al-Huniti NH, Freise KJ, et al. Change in 
erythropoietin pharmacokinetics following hematopoietic transplantation. Clin Pharmacol Ther. 
2007; 81(6):873–9. [PubMed: 17429351] 
33. Widness JA, Veng-Pedersen P, Modi NB, Schmidt RL, Chestnut DH. Developmental differences in 
erythropoietin pharmacokinetics: increased clearance and distribution in fetal and neonatal sheep. J 
Pharmacol Exp Ther. 1992; 261(3):977–84. [PubMed: 1602403] 
34. Takama H, Tanaka H, Nakashima D, Ogata H, Uchida E, Akizawa T, et al. Population 
pharmacokinetics of darbepoetin alfa in haemodialysis and peritoneal dialysis patients after 
intravenous administration. Br J Clin Pharmacol. 2007; 63(3):300–9. [PubMed: 16945116] 
35. Agoram B, Heatherington AC, Gastonguay MR. Development and evaluation of a population 
pharmacokinetic-pharmacodynamic model of darbepoetin alfa in patients with nonmyeloid 
malignancies undergoing multicycle chemotherapy. AAPS J. 2006; 8(3):E552–63. [PubMed: 
17025273] 
36. Agoram B, Sutjandra L, Sullivan JT. Population pharmacokinetics of darbepoetin alfa in healthy 
subjects. Br J Clin Pharmacol. 2007; 63(1):41–52. [PubMed: 16939525] 
37. Eckardt KU, Boutellier U, Kurtz A, Schopen M, Koller EA, Bauer C. Rate of erythropoietin 
formation in humans in response to acute hypobaric hypoxia. J Appl Physiol (1985). 1989; 66(4):
1785–8. [PubMed: 2732171] 
38. Lerner G, Kale AS, Warady BA, Jabs K, Bunchman TE, Heatherington A, et al. Pharmacokinetics 
of darbepoetin alfa in pediatric patients with chronic kidney disease. Pediatr Nephrol. 2002; 
17(11):933–7. [PubMed: 12432437] 
39. Kearns GL, Abdel-Rahman SM, Alander SW, Blowey DL, Leeder JS, Kauffman RE. 
Developmental pharmacology: drug disposition, action, and therapy in infants and children. N 
Engl J Med. 2003; 349(12):1157–67. [PubMed: 13679531] 
Roberts et al. Page 10
Clin Pharmacokinet. Author manuscript; available in PMC 2017 August 26.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Key Points
A population pharmacokinetic model for darbepoetin alfa in neonates with hypoxic-
ischemic encephalopathy was developed.
After a priori inclusion of birthweight on the volume of distribution and clearance, 
gestational age was inversely correlated with darbepoetin alfa clearance.
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Fig. 1. 
Observed erythropoietin concentrations vs. population-and individual-predicted 
erythropoietin concentrations for hypothermic darbepoetin alfa-treated neonates are 
presented in a and b, respectively, for the final model. The solid line represents the line of 
reference and the dotted line represents the spline of the model
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Fig. 2. 
The individual weighted residuals (IWRES) and normalized prediction distribution errors 
(NPDE) vs. time- and population-predicted erythropoietin concentrations are presented in a–
d. The solid line is the reference line at zero
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Fig. 3. 
Visual predictive check of the final neonatal darbepoetin alfa model. The blue shading 
represents the 10th and 90th percentiles. Pink shading represents the 50th percentile. The 
open circles and red shading represent data that did not fall within the 10th, 50th, or 90th 
percentiles. emp empirical, prctile percentile
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Table 1
Patient demographics
Characteristic Placebo (n = 10)a Darbepoetin alfa (n = 16)a
Sex (male) 4 10
GA (weeks) 38.1 ± 1.7 38.4 ± 1.2
PNA (h) 9.0 ± 1.4 9.7 ± 2.2
PMA (weeks) 38.1 ± 1.7 38.4 ± 1.1
BWT (kg) 3.09 ± 0.39 3.03 ± 0.43
Sarnat scoreb
 2 8 10
 3 2 6
BWT birthweight, GA gestational age, HIE hypoxic ischemic encephalopathy, PMA postmenstrual age, PNA postnatal age
a
n or mean ± standard deviation
b
The Sarnat Grading Scale of Hypoxic Ischemic Encephalopathy is a scoring system used to grade the severity of an HIE injury. Scores of 2 and 3 
represent moderate and severe HIE injuries, respectively
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Table 2
Final model parameter estimates
Parameters Mean parameter estimate 95 % confidence interval
V (L) 1.58 1.29–1.87
CL (L/h) 0.0465 0.0392–0.0537
θ 10.8 5.50–15.7
ω-BSV
 V 0.153 −0.161 to 0.467
 CL 0.205 0.054–0.356
 σ-RUV 0.421 0.325–0.517
CL clearance, BSV between-subject variability, RUV residual unexplained variability, V volume of distribution, θ represents the model-estimated 
coefficient for the effect of gestational age (weeks) on darbepoetin alfa clearance
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